<DOC>
	<DOCNO>NCT02186002</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability ACT-451840 healthy male subjects.Secondary objective : investigate pharmacokinetics ( PK ) ACT-451840 ; investigate effect food PK ACT-451840 ; evaluate urinary excretion ACT-451840 investigate antimalarial activity ACT-451840 .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics , Pharmacodynamics ACT-451840 Healthy Subjects ( Part A )</brief_title>
	<detailed_description />
	<criteria>Signed informed consent local language prior studymandated procedure . Body mass index ( BMI ) 18.0 28.0 kg/m2 ( inclusive ) screening . Systolic blood pressure 100145 mmHg , diastolic blood pressure 5090 mmHg , pulse rate 4590 beat per minute ( inclusive ) , measure dominant arm , 5 min supine position screening . 12lead electrocardiogram without clinically relevant abnormality , measure 5 min supine position screening . Hematology , coagulation , clinical chemistry , urinalysis test result deviate normal range clinically relevant extent screening . No clinically significant finding physical examination screening . Negative result urine drug screen screen . Ability communicate well investigator , local language , understand comply requirement study . Subject cover Health Insurance system and/or compliance recommendation National Law force relate biomedical research . If subject 's partner could become pregnant , reliable method contraception must use time first administration study medication 3 month follow administration last dose study medication . Known allergic reaction hypersensitivity excipient drug formulation ( ) . History clinical evidence disease and/or existence surgical medical condition might interfere absorption , distribution , metabolism excretion study drug . Previous history fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction . Documented history chronic liver gall bladder disease . Documented history hemolytic anemia . Veins unsuitable intravenous puncture either arm ( e.g. , vein difficult locate , access , puncture , vein tendency rupture puncture ) . Previous exposure study medication . Treatment another investigational drug within 3 month prior screen participation four investigational drug study within 12 month prior screen . Subject exclusion period previous clinical study . Subject receive 4,500 Euros indemnity participation biomedical research within 12 last month , include indemnity present study . History clinical evidence alcoholism drug abuse within 3year period prior screen . Excessive caffeine consumption , define 800 mg per day screening . Smoking within 3 month prior screen inability refrain smoke course study . Previous treatment prescribe overthecounter medication ( include herbal medicine St. John 's Wort ) within 2 week prior first study drug administration . Loss 250 mL blood within 3 month prior screen . Positive result hepatitis ( hepatitis B C ) serology , except vaccinated subject . Positive result human immunodeficiency virus serology screen . Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol . Legal incapacity limit legal capacity screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>ACT-451840</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>